Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.79 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.71 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.71 |
| ▸ | NQO2 | P16083 | 1/20 | 0.59 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869993 | 0.88 | MET (1.00) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL2568394 | 0.83 | MET (1.00) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL2571767 | 0.83 | MET (1.00) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL2572042 | 0.83 | MET (1.00) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL29869924 | 0.82 | MET (1.00) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL12489708 | 0.79 | MET (0.71) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL2570713 | 0.77 | MET (0.68) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL2569595 | 0.77 | MET (0.68) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL2572825 | 0.77 | MET (0.68) | METPDE4CPDE4DPDE3BPDE3A | |
| SCHEMBL12482749 | 0.76 | MET (0.67) | METPDE4CPDE4DPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107312009-B | Quinoline compound, preparation method, intermediate, pharmaceutical composition and application thereof | 上海医药集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |